Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.63 |
| ▸ | AR | P10275 | 7/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demegestone SCHEMBL1649297 | 1.00 | PGR (0.78) | PGRNR3C1ARNR3C2ESR1 | |
| Demegestone SCHEMBL6851326 | 1.00 | PGR (0.78) | PGRNR3C1ARNR3C2ESR1 | |
| Demegestone SCHEMBL28338894 | 0.98 | PGR (0.75) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL20959664 | 0.89 | PGR (0.75) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL19286040 | 0.88 | PGR (0.74) | PGRNR3C1ARNR3C2ESR1 | |
| Promegestone SCHEMBL37770 | 0.88 | PGR (1.00) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL544872 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL16016504 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL13918110 | 0.87 | PGR (0.67) | PGRNR3C1ARNR3C2ESR1 | |
| Promegestone SCHEMBL27977093 | 0.87 | PGR (0.94) | PGRNR3C1ARNR3C2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| EP-2116249-B2 | Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates | BAYER IP GMBH (DE) | 2023-04-05 | — | — | EP | claimed |
| CN-115175667-A | Lipid vesicle composition with permeation enhancer | 迪迪艾斯研究公司 | 2022-10-11 | — | — | CN | claimed |
| EP-4034087-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS Research Inc. (CA) | 2022-08-03 | — | — | EP | claimed |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2022-07-14 | — | — | US | claimed |
| CN-107812195-B | Stable pharmaceutical composition of (6S) -5-methyl-tetrahydrofolate calcium salt | 连云港金康和信药业有限公司 | 2021-04-20 | — | — | CN | claimed |
| WO-2021056106-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2021-04-01 | — | — | WO | claimed |
| EP-3689364-A1 | METHODS FOR THE USE OF PROGESTOGEN AS A GLUCOCORTICOID SENSITIZER | Shenzhen Evergreen Therapeutics Co., Ltd. (CN) | 2020-08-05 | — | — | EP | claimed |
| CN-110721393-A | Uterine stent and preparation method thereof | 易浦润（上海）生物技术有限公司 | 2020-01-24 | — | — | CN | claimed |
| US-10463666-B2 | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate | Merck & Cie (CH) | 2019-11-05 | — | — | US | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| CN-1088778-A | Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration | NOVEN PHARMA (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0573576-A1 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS. | NOVEN PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| WO-1992015289-A1 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0272918-B1 | DIFFUSION MATRIX FOR TRANSDERMAL DRUG ADMINISTRATION AND TRANSDERMAL DRUG DELIVERY DEVICES INCLUDING SAME | CYGNUS THERAPEUTIC SYSTEMS (US) | 1992-07-15 | — | — | EP | claimed |
| US-4911916-A | Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same | CYGNUS RESEARCH CORPORATION (US) | 1990-03-27 | — | — | US | claimed |
| EP-0337938-A2 | 19-Norprogesterone derivatives in the treatment of osteoporosis | SANDOZ AG (CH) | 1989-10-18 | — | — | EP | claimed |
| EP-0272918-A2 | Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same | CYGNUS THERAPEUTIC SYSTEMS (US) | 1988-06-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | PGRMC2, PGRMC1, PGR | PGR 3/4885NR3C1 1252/4885AR 74/4885 |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PGR 2965/4885NR3C1 3656/4885AR 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.